memo - Magazine of European Medical Oncology

, Volume 11, Issue 4, pp 297–300 | Cite as

Aggressive variant and treatment-related neuroendocrine prostate cancer: two different terms for the same disease?

  • Igor Tsaur
  • Christian ThomasEmail author
short review


Previously assumed to be rare, the prevalence of aggressive variants of prostate cancer has increased rapidly. This histologically heterogeneous group of cancers, including different forms of the neuroendocrine carcinoma of the prostate, share a common clinical course associated with a poor response to androgen deprivation treatment and fatal prognosis. Currently, the most commonly used terms are aggressive variant of prostate cancer and treatment-related neuroendocrine prostate cancer. The best treatment of these tumors in clinical routine is still being debated. Here, we highlight the clinically most relevant aspects of this heterogeneous disease and summarize recommendations for clinical routine.


Prostate cancer Aggressive variant Anaplastic Neuroendocrine Small cell 


Conflict of interest

I. Tsaur and C. Thomas declare that they have no competing interests.


  1. 1.
    Mottet N, Bellmunt J, Briers E, et al. EAU – ESTRO – ESUR – SIOG guidelines on prostate cancer. EAU Annual Congress Copenhagen 2018. Arnhem: EAU Guidelines Office; 2018. ISBN 978-9492671028.Google Scholar
  2. 2.
    Tilki D, Schaeffer EM, Evans CP. Understanding mechanisms of resistance in metastatic castration-resistant prostate cancer: the role of the androgen receptor. Eur Urol Focus. 2016;2(5):499–505.CrossRefPubMedGoogle Scholar
  3. 3.
    Zaffuto E, Pompe R, Zanaty M, Bondarenko HD, Leyh-Bannurah SR, Moschini M, et al. Contemporary incidence and cancer control outcomes of primary neuroendocrine prostate cancer: a SEER database analysis. Clin Genitourin Cancer. 2017;15(5):e793–e800.CrossRefPubMedGoogle Scholar
  4. 4.
    Aparicio A, Logothetis CJ, Maity SN. Understanding the lethal variant of prostate cancer: power of examining extremes. Cancer Discov. 2011;1(6):466–8.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Small EJ, Huang J, Youngren J, Sokolov A, Aggarwal RR, Thomas G, et al. Characterization of neuroendocrine prostate cancer (NEPC) in patients with metastatic castration resistant prostate cancer (mCRPC) resistant to abiraterone (Abi) or enzalutamide (Enz): preliminary results from the SU2C/PCF/AACR West Coast Prostate Cancer Dream Team (WCDT). J Clin Oncol. 2015;33(15 suppl):5003.Google Scholar
  6. 6.
    Wang W, Epstein JI. Small cell carcinoma of the prostate. A morphologic and immunohistochemical study of 95 cases. Am J Surg Pathol. 2008;32(1):65–71.CrossRefPubMedGoogle Scholar
  7. 7.
    Aggarwal R, Huang J, Alumkal JJ, et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J Clin Oncol. 2018; Scholar
  8. 8.
    Epstein JI, Amin MB, Beltran H, et al. Proposed morphologic classification of prostate cancer with neuroendocrine differentiation. Am J Surg Pathol. 2014;38:756–67.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Nadal R, Schweizer M, Kryvenko ON, et al. Small cell carcinoma of the prostate. Nat Rev Urol. 2014;11:213–9.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, et al. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res. 2013;19(13):3621–30.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Aparicio AM, Shen L, Tapia EL, et al. Combined tumor suppressor defects characterize clinically defined aggressive variant prostate cancers. Clin Cancer Res. 2016;22(6):1520–30.CrossRefPubMedGoogle Scholar
  12. 12.
    Amato RJ, Logothetis CJ, Hallinan R, Ro JY, Sella A, Dexeus FH. Chemotherapy for small cell carcinoma of prostatic origin. J Urol. 1992;147(3 Pt 2):935–7.CrossRefPubMedGoogle Scholar
  13. 13.
    Papandreou CN, Daliani DD, Thall PF, Tu SM, Wang X, Reyes A, et al. Results of a phase II study with doxorubicin, etoposide, and cisplatin in patients with fully characterized small-cell carcinoma of the prostate. J Clin Oncol. 2002;20(14):3072–80.CrossRefPubMedGoogle Scholar
  14. 14.
    Culine S, El Demery M, Lamy PJ, Iborra F, Avances C, Pinguet F. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers. J Urol. 2007;178(3 Pt 1):844–8. discussion 8.CrossRefPubMedGoogle Scholar
  15. 15.
    Flechon A, Pouessel D, Ferlay C, Perol D, Beuzeboc P, Gravis G, et al. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial. Ann Oncol. 2011;22(11):2476–81.CrossRefPubMedGoogle Scholar
  16. 16.
    Evans AJ, Humphrey PA, Belani J, van der Kwast TH, Srigley JR. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer. Am J Surg Pathol. 2006;30(6):684–93.CrossRefGoogle Scholar
  17. 17.
    de Leeuw R, Berman-Booty LD, Schiewer MJ, Ciment SJ, Den RB, Dicker AP, et al. Novel actions of next-generation taxanes benefit advanced stages of prostate cancer. Clin Cancer Res. 2015;21(4):795–807.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Aparicio A, Xiao L, Tapia ELN, Hoang A, Ramesh N, Wu W, et al. The aggressive variant prostate carcinoma (AVPC) molecular signature (‑MS) and platinum-sensitivity in castration resistant prostate cancer (CRPC). J Clin Oncol. 2017;35(15 suppl):5013.CrossRefGoogle Scholar
  19. 19.
    Corn PG, Tu S‑M, Zurita AJ, Subudhi SK, Araujo JC, Kim J, et al. A multi-institutional randomized phase II study (NCT01505868) of cabazitaxel (CAB) plus or minus carboplatin (CARB) in men with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol. 2015;33(15 suppl):5010.Google Scholar
  20. 20.
    Gillessen S, Attard G, Beer TM, Beltran H, Bossi A, Bristow R, et al. Management of atients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. Eur Urol. 2018;73(2):178–211.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Urology and Pediatric UrologyMainz University MedicineMainzGermany

Personalised recommendations